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Tamoxifen for prevention of breast cancer: extended long-
term follow-up of the IBIS-I breast cancer prevention trial
Jack Cuzick, Ivana Sestak, Simon Cawthorn, Hisham Hamed, Kaija Holli, Anthony Howell, John F Forbes, on behalf of the IBIS-I Investigators*
Summary
Background Four previously published randomised clinical trials have shown that tamoxifen can reduce the risk of breast 
cancer in healthy women at increased risk of breast cancer in the ﬁ rst 10 years of follow-up. We report the long-term 
follow-up of the IBIS-I trial, in which the participants and investigators remain largely masked to treatment allocation.
Methods In the IBIS-I randomised controlled trial, premenopausal and postmenopausal women 35–70 years of age 
deemed to be at an increased risk of developing breast cancer were randomly assigned (1:1) to receive oral tamoxifen 
20 mg daily or matching placebo for 5 years. Patients were randomly assigned to the two treatment groups by 
telephone or fax according to a block randomisation schedule (permuted block sizes of six or ten). Patients and 
investigators were masked to treatment assignment by use of central randomisation and coded drug supply. 
The primary endpoint was the occurrence of breast cancer (invasive breast cancer and ductal carcinoma in situ), 
analysed by intention to treat. Cox proportional hazard models were used to assess breast cancer occurrence and 
mortality. The trial is closed to recruitment and active treatment is completed, but long-term follow-up is ongoing. 
This trial is registered with controlledtrials.com, number ISRCTN91879928.
Findings Between April 14, 1992, and March 30, 2001, 7154 eligible women recruited from  genetics clinics and breast 
care clinics in eight countries were enrolled into the IBIS-I trial and were randomly allocated to the two treatment 
groups: 3579 to tamoxifen and 3575 to placebo. After a median follow up of 16·0 years (IQR 14·1–17·6), 601 breast 
cancers have been reported (251 [7·0%] in 3579 patients in the tamoxifen group vs 350 [9·8%] in 3575 women in the 
placebo group; hazard ratio [HR] 0·71 [95% CI 0·60–0·83], p<0·0001). The risk of developing breast cancer was 
similar between years 0–10 (226 [6·3%] in 3575 women in the placebo group vs 163 [4·6%] in 3579 women in the 
tamoxifen group; hazard ratio [HR] 0·72 [95% CI 0·59–0·88], p=0·001) and after 10 years (124 [3·8%] in 3295 women 
vs 88 [2·6%] in 3343, respectively; HR 0·69 [0·53–0·91], p=0·009). The greatest reduction in risk was seen in invasive 
oestrogen receptor-positive breast cancer (HR 0·66 [95% CI 0·54–0·81], p<0·0001) and ductal carcinoma in situ (0·65 
[0·43–1·00], p=0·05), but no eﬀ ect was noted for invasive oestrogen receptor-negative breast cancer (HR 1·05 [95% CI 
0·71–1·57], p=0·8).
Interpretation These results show that tamoxifen oﬀ ers a very long period of protection after treatment cessation, and 
thus substantially improves the beneﬁ t-to-harm ratio of the drug for breast cancer prevention.
Funding Cancer Research UK (UK) and the National Health and Medical Research Council (Australia).
Copyright © Cuzick et al. Open Access article distributed under the terms of CC BY.
Introduction
Breast cancer remains the most common type of cancer 
in women, with an estimated incidence of 1·6 million 
cases per year worldwide.1 Tamoxifen is a well-established 
and eﬀ ective treatment for oestrogen receptor-positive 
breast cancer.2 Four large randomised clinical trials have 
shown that tamoxifen reduces the incidence of oestrogen 
receptor-positive breast cancer in women at high risk of 
developing the disease.3–9 A recently published meta-
analysis of all prevention trials investigating selective 
oestrogen receptor modulators has shown that these 
drugs signiﬁ cantly reduce the incidence of all breast 
cancer (including ductal carcinoma)  in the ﬁ rst 10 years 
of follow-up  (hazard ratio [HR] 0·62 [95% CI 
0·56–0·69]).10 The HR for tamoxifen was 0·67 (95% CI 
0·59–0·76), but this was maintained for the entire 
10-year period (HR 0·62 [95% CI 0·53–0·73] in years 0–5 
and 0·78 [0·62–0·97] in years 5–10), whereas little follow-
up information was available after 5 years for the other 
selective oestrogen receptor modulators.10
The International Breast cancer Intervention Study  I 
(IBIS-I) was initiated in 1992 and recruited women at high 
risk of developing breast cancer to receive oral tamoxifen 
(20 mg daily) or matching placebo. The initial report 
showed a signiﬁ cant reduction (odds ratio [OR] 0·68 
[95% CI 0·50–0·92]) for all types of breast cancer 
(including ductal carcinoma in situ) after a median follow-
up of 4·2 years (IQR 2·67–5·58).6 After a median follow-up 
of 8 years (IQR 6·35–9·61), an updated report showed the 
signiﬁ cant reduction for all types of invasive breast cancer 
continued (risk ratio 0·73 [95% CI 0·58–0·91]) with 
tamoxifen.7 In both reports, a risk reduction by tamoxifen 
was only seen for oestrogen receptor-positive breast cancer 
and ductal carcinoma in situ. As has been reported 
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elsewhere,5,9,11,12 thromboembolic and gynaecological 
adverse events were increased with tamoxifen compared 
with placebo during active treatment, but the 8-year update 
showed that those side-eﬀ ects were mainly conﬁ ned to the 
active treatment period.5,7
With the exception of the Royal Marsden trial, in which 
median follow-up was 13 years,5 follow-up has been 
limited to 10 years or less for all other reports. In this 
Article, we report an updated analysis of the IBIS-I trial, 
which remains largely masked to treatment allocation.
Methods
Study design and participants
For this randomised controlled trial, eligible women 
35–70 years of age from 37 centres (genetics clinics and 
breast care clinics) in eight countries (the UK, Australia, 
New Zealand, Finland, Spain, Switzerland, Belgium, and 
Ireland; appendix p 2) and judged to be at increased risk 
of developing breast cancer were enrolled and randomly 
assigned in a 1:1 ratio to receive oral tamoxifen 20 mg 
daily or matching placebo for 5 years (appendix p 3). 
Patients were deemed to be at an increased risk of 
developing breast cancer based on a family history of 
breast cancer or abnormal benign breast disease. Speciﬁ c 
details about eligibility, entry, and exclusion criteria have 
previously been described in full.6,7 In brief, women had 
to have risk factors for breast cancer indicating at least a 
twofold increased risk for the disease in women aged 
45–70 years, whereas this risk needed to be higher than 
twofold for those younger than 45 years of age. Women 
with a history of any invasive cancer (excluding skin 
cancer), deep vein thrombosis, pulmonary embolism, or 
who wanted to become pregnant were excluded from trial 
participation. Women were deﬁ ned as postmenopausal if 
they had 12 consecutive months of amenorrhea or had an 
oophorectomy. Menopausal hormone therapy use was 
allowed during the trial. All participants provided written 
informed consent, after an initial discussion with their 
IBIS-I doctor and a consideration period of at least 24 h. 
The trial was approved by local ethics committees for 
each participating centre.
Procedures
Women were actively followed up for 5 years in the clinic 
or by telephone at 6-monthly intervals. All women have 
completed active treatment and are being followed up for 
occurrence of breast cancer, any other cancer, major 
adverse events, and death. In the UK, cancers and deaths 
are also reported to the IBIS-I central oﬃ  ce by the Oﬃ  ce 
for National Statistics. Adverse events were collected by 
annual postal questionnaires, which were sent directly to 
all participants and returned to the central oﬃ  ce. In the 
non-UK centres, annual questionnaires, annual clinic 
visits, or hospital notes were used to collect these data, 
supplemented by a national registry in Finland. 
Treatment allocation still remains largely masked for 
investigators and participating women who have not 
developed breast or any other cancer. An option was 
given to women who had not developed breast cancer 
after a minimum of 10 years’ follow-up on IBIS-I to take 
additional preventive therapy through enrolment into the 
IBIS-II trial.13
Randomisation and masking
Randomisation was done centrally by the IBIS study group 
(with no external input) by telephone or fax to a central 
oﬃ  ce in London, UK, for the European centres and in 
Sydney, Australia, for the centres in Australia and New 
Zealand. Balanced block randomisation was used and 
stratiﬁ ed by centre. Initial blocks of eight were created and 
were then randomly permuted into blocks of six or ten, to 
ensure that the ﬁ nal entry in each block was not predictable. 
The non-consecutive allocation sequence was generated by 
the IBIS-I programmer before study commencement. 
All IBIS-I personnel, participants, and clinicians were 
masked to treatment allocation and only the IBIS-I trial 
statistician (IS) had access to unmasked data.
Outcomes
The primary endpoint was the occurrence of any type of 
breast cancer (including ductal carcinoma in situ). 
Secondary endpoints included the occurrence of invasive 
oestrogen receptor-positive breast cancer, all-cause 
morta lity, and adverse events.
Statistical analysis
The cutoﬀ  date for this analysis was May 1, 2014, and 
events that occurred after this date were not included. All 
information received before Oct 1, 2014, was included in 
our analyses. Only major adverse events, such as death, 
other cancers, thromboembolic events and cardiovascular 
events, are reported in this analysis. All analyses were by 
intention to treat, and eﬃ  cacy endpoints were based on 
HRs from Cox proportional hazard models14,15 with 
corresponding 95% CIs. We checked proportionality 
using Schoenfeld residuals16 and we estimated survival 
curves using the Kaplan-Meier method.17 Women who 
joined the IBIS-II trial and were randomly allocated to 
active treatment (anastrozole) were censored at that point. 
We compared secondary endpoints using logistic 
regression. We used Fisher’s exact tests to compare 
adverse events between the tamoxifen and placebo groups 
when appropriate. All p values were two-sided. We used 
STATA version 12.1 for all analyses.
This study is registered with controlled-trials.com, 
number ISRCTN91879928.
Role of the funding source
The funders had no role in study design, collection of 
data or material, data analysis, interpretation of the data, 
or writing of the report. JC and IS had full access to all 
the raw data. The corresponding author had access to all 
the data and had ﬁ nal responsibility for the decision to 
submit for publication.
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Results
Between April 14, 1992, and March 30, 2001, 7169 women 
were initially enrolled into the trial and randomly 
assigned to the two treatment groups. 15 women were 
subsequently found to be ineligible because of previous 
breast cancer diagnosis (nine of those assigned to placebo 
and six assigned to tamoxifen), leaving a total of 
7154 women in the trial (3579 in the tamoxifen group and 
3575 in the placebo group). Median follow-up for this 
analysis was 16·0 years (IQR 14·1–17·6), and a total of 
110 043 women-years of follow-up have been accrued 
(tamoxifen: 55 419, placebo: 54 624). Most women (6639 
[93%] of 7154) have had more than 10 years of follow-up, 
and the cumulative number of women-years of follow-up 
are 69 074 before 10 years and 40 969  thereafter. Median 
age at study entry was 49·9 years (IQR 46·0–55·0), and 
3858 (54%) of 7154 women were postmenopausal. 4002 
(56%) of 7154 had a body-mass index (BMI) higher than 
25 kg/cm², and 2876 (40%) of 7154 used menopausal 
hormone therapy at some point during the active 
treatment phase of the trial. Use of this treatment during 
the trial was slightly, but not signiﬁ cantly, higher in 
women assigned to tamoxifen.7 Appendix p 3 shows 
other baseline demographics. Most women (6939 [97%] 
of 7154) were entered into the trial because of a family 
history of breast cancer, but a few (572 [8%]) were enrolled 
on the basis of having a benign breast lesion associated 
with increased breast cancer risk.
At the time of data cutoﬀ , treatment allocation still 
remains largely masked for investigators and 
participating women who have not developed breast or 
any other cancer (2702 [75·5%] of those assigned to 
tamoxifen vs 2646 [74·0%] of those who received placebo). 
After 10 years’ follow-up, 603 women joined the IBIS-II 
trial, of whom 302 were randomly assigned to anastrozole 
and were censored at that time.
A total of 601 breast cancers were reported before the 
cutoﬀ  date of May 1, 2014 (251 [7·0%] in 3579 women in 
the tamoxifen group vs 350 [9·8%] of 3575 in the placebo 
group; table 1). We found a signiﬁ cant reduction in the 
occurrence of all breast cancers in the tamoxifen group 
compared to the placebo group (HR 0·71 [95% CI 
0·60–0·83], p<0·0001). We observed a signiﬁ cant 
reduction in the ﬁ rst 10 years of follow-up (HR 0·72 
[95% CI 0·59–0·88], p=0·001), which was slightly greater 
in subsequent years (0·69 [0·53–0·91], p=0·009). Figure 1 
shows the Kaplan-Meier-based cumulative incidence 
curves for all breast cancers (and for oestrogen receptor-
positive invasive cancers) according to follow-up period. 
After 20 years of follow-up, the estimated risk of 
developing all types of breast cancer was 12·3% (95% CI 
10·1–14·5) in the placebo group compared with 7·8% 
(95% CI 6·9–9·0) in the tamoxifen group, indicating that 
the number needed to treat for 5 years to prevent one 
breast cancer in the next 20 years was 22 (95% CI 19–26). 
Figure 2 shows the hazard rates by year for tamoxifen and 
placebo and conﬁ rms the continuing beneﬁ t of tamoxifen 
versus placebo over the entire 20-year follow-up period. A 
test for proportionality of hazards indicated no departure 
from the proportional hazards assumption during the 
entire follow up period (p=0·9).
A similar pattern was observed for invasive oestrogen 
receptor-positive breast cancer (table 1, ﬁ gure 1). 
A signiﬁ cant reduction in cancer occurrence with 
tamoxifen was recorded in the ﬁ rst 10 years of follow-up, 
which was maintained in subsequent years (table 1, 
ﬁ gure 2). The number needed to treat to prevent one 
invasive oestrogen receptor-positive breast cancer was 29 
(95% CI 26–34).
A signiﬁ cant reduction for tamoxifen was also recorded 
for ductal carcinoma in situ, but only in the ﬁ rst 10 years 
of follow-up (table 1). No signiﬁ cant eﬀ ect with tamoxifen 
was recorded for invasive oestrogen receptor-negative 
breast cancer (table 1, ﬁ gure 3). There were more 
oestrogen receptor-negative breast cancers in the 
tamoxifen group after 10 years of follow-up than in the 
placebo group (ten cancers in the tamoxifen group vs 
four in the placebo group; HR 2·45 [0·77–7·82], p=0·13). 
The preventive eﬀ ects of tamoxifen did not diﬀ er 
according to tumour size, nodal status, or grade, since 
there was substantial overlap in the conﬁ dence intervals 
and no signiﬁ cant trends (table 1, appendix p 4).
Women who had menopausal hormone therapy during 
the 5 years of active treatment had signiﬁ cantly less 
beneﬁ t from tamoxifen than those who did not (p=0·04; 
table 1, ﬁ gure 3). This eﬀ ect was larger for women who 
developed invasive oestrogen receptor-positive cancers 
(users of menopausal hormone therapy HR 0·87 [95% CI 
0·64–1·19] vs non users 0·55 [0·42–0·72]; p=0·03). There 
was no signiﬁ cant diﬀ erence between women aged 
50 years or younger than in older women throughout the 
follow-up periods (table 1, ﬁ gure 3). No interactions were 
recorded with other demographic factors (appendix p 4).
Figure 1: Cumulative incidence of breast cancers over time
All breast cancers (solid lines) and invasive oestrogen receptor-positive breast cancers (dashed lines), according to 
treatment group and duration of follow-up.
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In total, 666 cancers other than breast cancer were 
reported (table 2). 315 (8%) other cancers occurred in 
women in the placebo group compared with 351 (9%) in 
the tamoxifen group (OR 1·13 [0·96–1·32], p=0·3) 
(table 2). Although not signiﬁ cant, there were more 
endometrial cancers in the tamoxifen group than the 
placebo group, but the excess was conﬁ ned to the ﬁ rst 
5 years of active treatment, with no subsequent diﬀ erence 
(table 2). Other gynaecological cancers were distributed 
similarly between the two treatment groups (table 2). 
Signiﬁ cantly fewer gastrointestinal cancers occurred in 
women receiving tamoxifen than in those receiving 
placebo (42 in the tamoxifen group vs 63 in the placebo 
group; OR 0·66 [95% CI 0·44–0·99], p=0·038; table 2). 
Non-melanoma skin cancers were signiﬁ cantly increased 
in the tamoxifen group, whereas there was a similar 
incidence of melanoma skin cancers between the two 
treatment groups (table 2). More cases of lung cancer were 
reported with tamoxifen (32 cases) than with placebo 
(24 cases), although this diﬀ erence was not signiﬁ cant and 
was only observed in the ﬁ rst 10 years of follow-up 
(table 2). No speciﬁ c treatment or time-period diﬀ erences 
were recorded for other cancers (table 2).
Further data about minor side-eﬀ ects were not recorded 
since the last publication7 because no eﬀ ects were 
anticipated to occur more than 5 years after completion of 
treatment. However, information about major 
thromboembolic, cerebrovascular, and cardiac events 
continued to be collected (appendix p 3). At last data 
cutoﬀ  (May, 2014), there was a signiﬁ cantly higher 
incidence of deep vein thrombosis in women receiving 
tamoxifen than those receiving placebo (50 [1·4%] of 3579 
women receiving tamoxifen vs 29 [0·8%] of 3575 women 
receiving placebo; OR 1·73 [95% CI 1·07–2·85], p=0·02; 
appendix p 3). However, the increased risk was only 
during the ﬁ rst 10 years of follow-up (46 [1·3%] in the 
tamoxifen group vs 25 [0·7%] in the placebo group; 
OR 1·87 [95% CI 1·11–3·18], p=0·011). No signiﬁ cant 
diﬀ erences between treatment groups were recorded for 
major cardiovascular events (13 [<1%] of 3579 women in 
the tamoxifen group vs 17 [<1%] of 3575 women in the 
placebo group; OR 0·76 [95% CI 0·34–1·67],  p=0·46) or 
cerebrovascular accidents (30 [1%] tamoxifen vs 28 [1%] 
placebo; 1·07 [0·62–1·86], p=0·80).
A total of 348 deaths were reported up until the cutoﬀ  
date (182 [5·1%] of 3579 women in the tamoxifen group 
and 166 [4·6%] of 3575 women in the placebo group; 
table 3). There was no signiﬁ cant diﬀ erence in mortality 
between groups (OR 1·10 [95% CI 0·88–1·37], p=0·4). 
The higher number of deaths in the tamoxifen group were 
conﬁ ned to the ﬁ rst 10 years of follow-up (86 deaths in the 
tamoxifen group vs 71 in the placebo group), and a similar 
number of deaths were reported thereafter (96 tamoxifen 
vs 95 placebo). Table 3 shows the speciﬁ c causes of deaths. 
Overall, tamoxifen had no eﬀ ect on breast cancer-speciﬁ c 
mortality (31 deaths with tamoxifen vs 26 with placebo; 
OR 1·19 [95% CI 0·68–2·10], p=0·8). A few more breast 
cancer deaths occurred in the tamoxifen group after 
10 years of follow-up, although this diﬀ erence was not 
signiﬁ cant (18 tamoxifen vs nine placebo; OR 2·00 
[0·85–5·06], p=0·08). There was no evidence to suggest 
that these late deaths were associated with use of 
menopausal hormone therapy during the trial 
(six tamoxifen vs three placebo; p=0·33) or the 
development of oestrogen receptor-negative tumours 
Figure 2: Smoothed annual hazard rate curves for breast cancer
All breast cancers (solid lines) and invasive oestrogen receptor-positive breast cancers (dashed lines), according to 
treatment group.
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Figure 3: Forest plot for subgroup analyses according to follow-up periods (0–10 years vs ≥10 years)
Horizontal lines are 95% CIs.
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(four tamoxifen vs two placebo; p=0·42). Five women in 
the tamoxifen group died from endometrial cancers (four 
within the ﬁ rst 10 years) compared with none in the 
placebo group (p=0·06). We recorded no signiﬁ cant 
diﬀ erences in other cancers or causes of death, although 
there was a non-signiﬁ cant increase in respiratory deaths 
occurred in the tamoxifen group after 10 years 
(13 tamoxifen vs six placebo; OR 2·17 [95% CI 0·77–6·96], 
p=0·1).
Discussion
This extended analysis of the IBIS-I trial provides 
important evidence showing that 5 years of tamoxifen 
treatment reduces the incidence of breast cancer for at 
least 20 years. In our previous report after an 8-year median 
follow-up,7 337 breast cancers were reported. In the current 
report with 16-year median follow-up, the number of 
breast cancers has almost doubled to 601, of which 212 
(35%) have occurred after 10 years of follow-up. 
The preventive eﬀ ect of tamoxifen has remained similar 
throughout this 20-year period (panel). Reductions were 
recorded for invasive oestrogen receptor-positive cancers 
and ductal carcinoma in situ, but not for invasive oestrogen 
receptor-negative cancers. Of interest was a small, non-
signiﬁ cant increase in oestrogen receptor-negative 
tumours after 10 years (ten cases with tamoxifen vs four 
with placebo). An increase in these tumours was also seen 
in the selective oestrogen receptor modulator meta-
analysis  but only in years 5–10,10 which was signiﬁ cant for 
all selective oestrogen receptor modulators (p=0·02), but 
not for tamoxifen alone (p=0·4). However, no follow-up 
was available after 10 years. This ﬁ nding could be due to 
tumours that would have presented earlier as oestrogen 
receptor-positive cancers, but were transiently held in 
check by tamoxifen, and then later escaped the need for 
hormonal stimulus and subsequently appeared as 
oestrogen receptor-negative cancers. Follow-up beyond 
10 years is limited to the Royal Marsden trial5 in which 
treatment was given for 8 years and median follow up was 
13 years. Unlike other trials, the Royal Marsden trial 
reported little eﬀ ect of tamoxifen in the 8 years of treatment 
(risk ratio 1·06 [95% CI 0·70–1·70], p=0·8), but a reduction 
in invasive cancers after 8 years (38 cancers vs 56 cancers; 
HR 0·67 [95% CI 0·44–1·01), p=0·05), with larger eﬀ ects 
for oestrogen receptor-positive than for oestrogen receptor-
negative cancers. The reason for a diﬀ erence between early 
and late eﬀ ects is unclear, but that trial randomly assigned 
a group of women who were younger and at higher risk of 
breast cancer than those in our trial, which could be 
relevant. Nevertheless, the agreement between these two 
trials regarding the long-term eﬀ ectiveness of tamoxifen is 
important and provides strong evidence for a long-lasting 
reduction in number of cases of breast cancer.
The beneﬁ t of tamoxifen was signiﬁ cantly greater in 
women who did not use menopausal hormone therapy 
during the treatment period than in those who used this 
therapy, indicating the clear loss of eﬃ  cacy of tamoxifen 
when menopausal hormone therapy is used concomitantly. 
This ﬁ nding was not reported in the Royal Marsden trial5,9 
or in the Italian trial (the Italian Tamoxifen Prevention 
Study),11,12 and menopausal hormone therapy use was not 
allowed in the NSABP-P1 trial.3,4 Understanding how the 
type and duration of menopausal hormone therapy aﬀ ects 
breast cancer risk is thus an important question that has to 
be addressed. Full details are being abstracted (in a 
manuscript currently being prepared by the IBIS-I team) 
and will be presented elsewhere. Of interest was the large 
eﬀ ect of tamoxifen on the incidence of ductal carcinoma in 
situ in the ﬁ rst 10 years and little eﬀ ect thereafter. In the 
overview of selective oestrogen receptor modulators,10 the 
eﬀ ect of tamoxifen and other selective oestrogen receptor 
modulators for ductal carcinoma in situ was largely 
restricted to the ﬁ rst 5 years, with little eﬀ ect in years 5–10, 
but no data are available after 10 years. The relevance of 
this for breast cancer prevention is not clear, but since 
ductal carcinoma in situ is a precursor lesion, it could 
indicate that the preventive eﬀ ect of tamoxifen will not be 
maintained indeﬁ nitely.
All women have completed the active follow-up portion 
of this trial, but continue to be monitored by a range of 
methods. In the UK and Finland, where 4412 (61·7%) of 
the participants were recruited, follow-up is covered by 
national ﬂ agging systems and so will be essentially 
complete for cancer and death. These data were augmented 
by annual questionnaires in the UK and clinic notes in 
Finland. For Australia and New Zealand (2676 [37·4%] of 
cases), annual questionnaires were used for all participants 
0–10 year follow-up 
period
≥10 year follow-up 
period
Overall
Placebo 
(n=71)
Tamoxifen 
(n=86)
Placebo 
(n=95)
Tamoxifen 
(n=96)
Placebo 
(n=166)
Tamoxifen 
(n=182)
Cancer
Breast 17 (24%) 13 (15%) 9 (9%) 18 (19%) 26 (16%) 31 (17%)
Genitourinary 7 (10%) 11 (13%) 9 (9%) 10 (10%) 16 (10%) 21 (12%)
Digestive 8 (11%) 10 (12%) 12 (13%) 11 (11%) 20 (12%) 21 (12%)
Lung 9 (13%) 9 (10%) 17 (18%) 9 (9%) 26 (16%) 18 (10%)
Lymphatic 2 (3%) 2 (2%) 0 2 (2%) 2 (1%) 4 (2%)
Melanoma 0 1 (1%) 1 (1%) 4 (4%) 1 (1%) 5 (3%)
Other 7 (10%) 11 (13%) 6 (6%) 8 (8%) 13 (8%) 19 (10%)
Cardiac 3 (4%) 10 (12%) 11 (12%) 2 (2%) 14 (8%) 12 (7%)
Deep vein thrombosis or 
pulmonary embolism
2 (3%) 3 (4%) 1 (1%) 1 (1%) 3 (2%) 4 (2%)
Stroke or cerebrovascular 
accident
5 (7%) 4 (5%) 7 (7%) 6 (6%) 12 (7%) 10 (5%)
Infection 0 1 (1%) 3 (3%) 1 (1%) 3 (2%) 2 (1%)
Neurological 1 (1%) 0 1 (1%) 3 (3%) 2 (1%) 3 (2%)
Respiratory 2 (3%) 2 (2%) 6 (6%) 13 (14%) 8 (5%) 15 (8%)
Other 8 (11%) 8 (9%) 10 (11%) 7 (7%) 18 (11%) 15 (8%)
Unknown 0 1 (1%) 2 (2%) 1 (1%) 2 (1%) 2 (1%)
Percentages are proportions of all deaths for given treatment and time period.
 Table 3: Speciﬁ c causes of death according to treatment group and follow-up period
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except for 44 women who have withdrawn consent for 
additional follow-up (and these women were censored at 
that time). Additionally, for this analysis we obtained up-to-
date clinical follow up for the remaining few cases in 
Switzerland and Belgium (63 [0·9%] of cases). Long-term 
follow-up was not undertaken in Spain and Ireland (three 
[<0·1%] cases). Thus, we believe that the data for breast 
cancer and deaths are virtually complete. Data about other 
major but non-fatal side-eﬀ ects (eg, strokes and myocardial 
infarctions) are substantially complete but are not covered 
by national ﬂ agging systems and so are only obtained from 
clinic visits, note review, and postal questionnaires. Data 
for minor side-eﬀ ects (eg, vasomotor symptoms or 
gynaecological events) were reported after 8 years’ median 
follow-up,7 and since these were mostly conﬁ ned to the 
active treatment period they have not been collected 
beyond 10 years of follow-up.
Overall there was no signiﬁ cant diﬀ erence in all-cause 
mortality between treatment groups, and the excess of 
death in the tamoxifen group was smaller than in 
previous reports.6,7 The number of deaths was very similar 
in the two groups after 10 years. Despite there being no 
signiﬁ cant diﬀ erence in the number of deaths from 
breast cancer between treatment groups, there were 
more deaths from breast cancer in the tamoxifen group; 
this outcome could not be linked to use of menopausal 
hormone therapy or the occurrence of oestrogen receptor-
negative breast cancer. Endometrial cancer was more 
common in the tamoxifen group than in the placebo 
group during active treatment, but similar thereafter. 
However, deaths from endometrial cancer were more 
frequent in the tamoxifen group (ﬁ ve) than in the placebo 
group (none), and all but one occurred after 5 years of 
active treatment. Excess deaths from endometrial cancer 
have also been reported in the overview of adjuvant 
Panel: Research in context
Systematic review
A systematic review of the use of tamoxifen and other selective oestrogen receptor 
modulators for breast cancer prevention has recently been published,10 but contained 
follow-up for only 10 years. This review included the four randomised trials (including the 
present IBIS-I trial) that have reported about the use of tamoxifen for prevention of breast 
cancer.3–7,9,11,12 We identiﬁ ed one only trial (the Royal Marsden trial) with follow-up beyond 
10 years,5 but the number of breast cancers after 8 years in this trial was only 94, 
compared with 212 after 10 years for IBIS-I in our report.
Interpretation
The results from the present trial provide important additional evidence that 5 years of 
tamoxifen treatment reduces the incidence of breast cancer in high-risk women for the 
entire follow-up period. Eﬀ ect sizes for tamoxifen were signiﬁ cantly greater in women who 
did not take menopausal hormone therapy during the treatment period—a ﬁ nding that has 
not been reported previously. No eﬀ ect on all-cause or breast cancer mortality was 
recorded, but an increase in deaths from endometrial cancer was conﬁ rmed as noted in the 
adjuvant trials.18 Our results substantially improve the beneﬁ t-to-harm ratio for the use of 
tamoxifen to prevent breast cancer in high-risk women, with an estimated 22 women 
being needed to be treated for 5 years to prevent one breast cancer in the next 20 years.
tamoxifen trials,18 with an annual rate slightly higher 
than reported here (1·9 vs 1·1 per 10 000 women-years), 
which at least partly represents the higher number of 
postmenopausal women in the adjuvant studies. These 
rates do not adjust for women who had undergone a 
hysterectomy, so the risk in women with a uterus would 
be about 50% higher than those reported here in IBIS-I. 
The apparent, although not statistically signiﬁ cant, 
excess  of deaths from respiratory causes has not been 
reported in the overview of tamoxifen adjuvant trials, 
with only two respiratory deaths recorded in the 15-year 
follow-up18 (Pan H, University of Oxford, UK, personal 
communication), so this ﬁ nding might well be due to 
chance alone.
The fact that the reduced incidence of breast cancer with 
tamoxifen has not translated into a mortality reduction is 
of some concern. However, the ratio of deaths from breast 
cancer (57) to incident cases of breast cancer (601) is only 
9·5%, so the power for analysis of mortality (which our 
study was not powered to assess) is much lower than that 
for incidence. Additionally, the eﬀ ect on mortality is 
expected to be lower than that for incidence since only 
oestrogen receptor-positive cancers are prevented by 
tamoxifen. We previously estimated that the recorded 
reduction in incidence would lead to an 18% reduction in 
breast cancer mortality.19 If this were the case, the power to 
detect such a reduction at this stage (with two-sided 5% 
signiﬁ cance level) would be only 12%, so the absence of a 
signiﬁ cant diﬀ erence is not surprising.
In conclusion, our results clearly show a long-term 
eﬀ ect of 5 years of tamoxifen treatment to prevent breast 
cancer in the next 20 years. No new late toxicity has been 
identiﬁ ed, although the early excess of endometrial cancer 
in the tamoxifen group has translated into an increased 
number of deaths, which, although not signiﬁ cant in our 
study, has been reported in adjuvant trials of tamoxifen 
and therefore is important in making the decision to use 
the drug. These results substantially improve the beneﬁ t-
to-harm ratio for the use of tamoxifen to prevent breast 
cancer in high-risk women.
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